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ABSTRACT 
This review summarizes the effects of resveratrol in neurodegenerative 
diseases and speculates on the direction the field will take in the immediate 
future. In particular, we emphasize studies on the effects of resveratrol on new 
pathways related to neurodegenerative diseases such as inflammatory 
processes, mitochondrial biogenesis and its control through gamma coactivator 
1-α (PGC1α), and the role of the tandem sirtuin 1 (SIRT1) and AMP-activated 
protein kinase (AMPK) in neurodegeneration and in neurohormesis. While not 
all reported results are free from controversy, the demographic shift toward an 
older population makes compounds with this broad spectrum of potential clinical 
applications particularly interesting. 
 
Keywords: Resveratrol, polyphenols, sirtuin 1, aging, neurodegeneration, 
inflammation, autophagy. 
Introduction 
Resveratrol is a natural polyphenol that has been extensively investigated and 
has been proposed to protect Low-density lipoproteins (LDL) against oxidation, 
to have cancer chemopreventive activity, to modulate the hepatic synthesis of 
triglyceride and cholesterol and to inhibit platelet clotting [1]. Moreover, it has 
recently been discovered to play an important role in neuroprotection [2]. At 
present, many studies on resveratrol are available; these address its effects on 
cancer and heart disease, its neuroprotective activity, and its effects on 
longevity, inflammation, obesity and metabolism [3]. 
Up until now, many studies have shown that resveratrol extends the maximum 
or median life span and improves age-related markers in several species such 
as yeast [4], worms and flies [5], fish [6] and mice [7,8].  
In spite of these findings, it remains to be clarified whether the effects of 
resveratrol on health and aging are strictly sirtuin 1 -dependent or modify other 
sirtuin 1-independent molecular pathways related to the aging process. 
 
 What is resveratrol? Where is it found? 
Resveratrol (3,5,4′-trihydroxystilbene) is a non-flavonoid polyphenolic 
compound consisting of two aromatic rings attached by a methylene bridge [9]. 
With respect to its physical-chemical properties, resveratrol is a whitish solid 
powder with molecular formula C14H12O3, a molecular weight of 228.25 g/mol 
and a melting point of 253-255ºC. It is a soluble compound in lipids, ethanol and 
dimethyl sulfoxide , but practically insoluble in water. However, it is highly 
permeable and therefore considered as a Biopharmaceutics Classification 
System (BCS) class II compound, characterized high permeability and low 
solubility  predicting a high the intestinal absorption. It exists as two isomers: 
trans-, which is more active biologically, and cis-, which is more unstable and 
not commercialized. 
It is a natural phenol produced by 72 different plant species, including 
grapevines, pines and legumes. It is also found in high concentrations in 
peanuts, soybeans and pomegranates. When grapes are infected with Botrytis 
cinerea, it leads to the exclusive synthesis of resveratrol in the leaf epidermis 
and grape skins. During white wine production, grape skins are not fermented, 
so only red wine contains noticeable amounts of resveratrol [9]. Resveratrol 
also accumulates in plants in response to other exogenous factors such as 
injury or UV irradiation, in addition to other fungal infections.  
Many compounds have been identified in red wine, including flavonols such as 
myricetin, kaempferol and the predominant quercetin, the flavan-3-ol monomers 
catechin and epicatechin, oligomeric and polymeric flavan-3-ols, 
proanthocyanidins, anthocyanins, phenolic acids such as gallic acid, caftaric 
acid, caffeic acid and p-coumaric acid, and the stilbene resveratrol. Thus, red 
wine appears to be the richest source of resveratrol through the skins, seeds, 
and stems of the grapes, where it is produced [9]. 
Resveratrol was first isolated from the root of Polygonum cuspidatum, a plant 
used in traditional Chinese and Japanese medicine [2], and was initially 
characterized as a phytoalexin [10]. In the 1990s, resveratrol was postulated to 
explain some of the positive effects of red wine. The term “the French paradox” 
was coined in 1992 when it was observed that French people presented a low 
incidence of coronary heart disease despite having a diet rich in saturated fats. 
This led researchers to reflect on a possible reason and to propose that the high 
percentage of wine consumed in France was the cause of the apparent 
discrepancy. It was suggested that a reduction in platelet aggregation may be 
the main factor behind the effect on coronary heart disease. Several studies 
have been carried out that show a correlation between a low-to-moderate wine 
intake and lower mortality from cardiovascular and cerebrovascular diseases. It 
is also significant that heavy consumption of alcohol, including wine, increases 
the prevalence of myocardial infarction, cardiomyopathy, cardiac arrhythmias, 
hypertension, hemorrhagic shock and sudden death, which confirms that such 
consumption is harmful to the cardiovascular system [9]. Since these initial 
findings, many studies have shown that resveratrol can prevent or slow the 
progression of cancers, cardiovascular diseases and ischemic injuries. 
Moreover, it has been observed to enhance stress resistance and life span, not 
only in minor species such as the worm or fly [11], but also in mammals [8]. 
In terms of toxicity and safety, current information available on resveratrol is 
limited. Oral administration of a 20-mg/kg dose of resveratrol in rats showed 
harmful effects on growth, hematology, biochemistry and histopathology. On the 
other hand, a dose of 18,000 mg/kg led to death in most of the animals. In 
humans, single doses up to 10 g of resveratrol were well tolerated [12]. 
An important limitation of resveratrol is its low bioavailability due to its rapid 
metabolism into glucuronated and sulfonated conjugated forms [2, 13].It has 
been observed that 46% of the drug is absorbed and results in conjugated 
forms [14]. An important aspect here is the presence of efflux proteins such as 
Multidrug resistance-associated protein 2 (MRP2) and breakpoint cluster region 
protein (BCR), which secrete conjugated forms to the intestinal lumen. This 
could restrict absorption [15]. Nevertheless, other studies have shown that 
hepatic metabolism is the main factor that affects the bioavailability of 
resveratrol. A study in humans revealed that after one hour of intravenous 
administration, only glucuronated and sulfonated forms were found in plasma 
[16]. Therefore, it is thought that metabolites could be partly responsible for the 
biological effects of resveratrol. Nonetheless, high doses of the compound 
would be required to approach the active concentration described in animal 
models. 
A noteworthy feature of resveratrol is its capacity to cross the blood-brain 
barrier in animal models. When intraperitoneally administered, resveratrol 
increased the activity of antioxidant enzymes in the brains of healthy rats [17]. 
Furthermore, a study in gerbils demonstrated that resveratrol reaches a 
concentration peak in the brain four hours after intraperitoneal administration 
[18]. 
Antioxidant properties of resveratrol: a major neuroprotective role? 
Brain oxidative stress caused by a redox imbalance forms the basis of a 
number of diseases, including most age-related neurodegenerative diseases. 
The brain is the most metabolically active organ in the body, whereas it has a 
relatively low antioxidant defense and a high content of membrane lipids 
susceptible to oxidation. Therefore, brain tissue maintains a fragile redox 
homeostasis and neurons are particularly vulnerable to free radical damage. In 
such scenery, the neuroprotective potential of an antioxidant compound like 
resveratrol, which is accessible to the brain through diet, may be enormous. 
Neurohormesis is a response to a moderate level of stress that enhances the 
nervous system’s resistance to more severe stress that might be lethal or cause 
dysfunction or disease [19]. Neurohormetic phytochemicals such as resveratrol, 
sulforaphane, curcumin and catechins protect neurons against injury and 
disease. 
It has long been known that trans-resveratrol, and with less potency the isomer 
cis-resveratrol, are effective antioxidants [20]. Their stilbene structure with two 
phenol rings means that it scavenges a variety of free radicals, including lipid 
peroxyl and carbon-centered radicals, and reactive oxygen species. The 
neuroprotective effects of resveratrol, resulting from its antioxidant activity, have 
been widely reported. For instance, resveratrol treatment decreases markers of 
oxidative damage in in vivo and in vitro hypoxia-ischemia models, which have a 
high level of free radical formation. Resveratrol protected cultured neurons from 
senescence-accelerated mouse strain SAMP8 against their increased 
vulnerability to oxidative damage [21], and against amyloid beta oxidative 
damage [22]. The antioxidant potency of resveratrol is also due to its capacity to 
induce the expression of antioxidant enzymes such as superoxide dismutase 
and glutathione peroxidase in SAMP8 mice [23] and heme oxygenase-1 in a rat 
model of Alzheimer’s disease [24]. Recent studies have revealed that 
resveratrol modulates genes related to redox pathways. It induced the 
transcriptional coactivator peroxisome proliferator-activated receptor PGC-1α, 
which is a master regulator of oxidative stress and mitochondrial metabolism, in 
a mouse model of Parkinson’s disease [25] and upregulated the expression of 
the transcription factor erythroid 2-related factor 2 (Nrf2) in an ischemia rat 
model [26]. The Nrf2-signaling pathway activates the transcription of many 
genes that are crucial for protection against oxidative stress. Resveratrol 
treatment increased the expression and nuclear translocation of forkhead 
transcription factors of the FOXO3a class in dopaminergic cells [27]. FOXO 
genes mediate the first line of defense against oxidative stress. Neuroprotection 
against oxidative stress by resveratrol is at least partially mediated through the 
activation of the SIRT1 pathway.  
Cellular oxidative stress resulting from mitochondrial dysfunction is central to 
the aging process and neurodegenerative disorders such as Alzheimer’s 
disease and Parkinson’s disease. Oxidative stress also occurs in strokes and 
cerebrovascular conditions, which are more common with advancing age and 
increase the risk of dementia. Resveratrol alleviates the oxidative stress that 
leads to neurodegeneration. Consequently, this aspect of resveratrol’s 
pleiotropic activity may help increase health span. 
Resveratrol and aging: key role in SIRT1 pathway 
Mammals express up to seven sirtuins (SIRT1–7). Sirtuins are a family of 
deacetylases dependent on NAD+ with a conserved catalytic core domain, but 
different protein sequences flanking their catalytic core domain and different 
subcellular localization. In particular, SIRT1 can translocate from cytoplasm to 
the nucleus, where it deacetylates nucleosomal histones at specific residues 
and contributes to telomere maintenance [28]. This may partly explain their 
capacity to extend life span. On the other hand, SIRT1  deacetylates other non-
histone substrates, including components of DNA repair machinery such as 
Ku70 [29] and Poly (ADP-ribose) polymerase (PARP) [30], and many 
transcription factors related to energetic metabolism such as PGC1-α [31], 
Hypoxia-inducible factor 1α (HIF-1α) [32] and Peroxisome proliferator-activated 
receptor –α (PPAR-α) [33], as well as other transcription factors such as p53 
[34,35] Forkhead box (FOXO) family transcription factors [36] and nuclear factor 
kappa B (NFƙB) [37], which are involved in apoptosis, oxidative stress and 
inflammation, respectively. 
 
It is known that caloric restriction (CR) has beneficial effects on mammalian 
health, extends life span and delays the onset of age-associated diseases such 
as cancer, diabetes and cardiovascular diseases in non-human primates [38]. 
Recent studies have shown similar effects of CR on the health of monkeys, 
although an increase in life span was not observed in this particular study [39], 
authors concluded that a separation between health effects, morbidity and 
mortality, study design, husbandry and diet composition may strongly affect the 
life-prolonging effect of CR, to explain discrepancies with others reports where 
showed increases in life span in monkeys under CR was showed [38].  
 
Resveratrol mimics several aspects of calorie restriction [40, 41], and CR 
effects appear to be, in part, dependent on SIRT1 [29]. Similar effects are 
produced by other small SIRT1 activators, among others SRT501 and 
SRT1720, that replicate signaling pathways triggered by CR [42, 43]. 
Furthermore, SIRT1 transgenic mice have phenotypes resembling CR [44]. 
These SIRT1 transgenic mice are leaner than littermate controls; are more 
metabolically active; display reductions in blood cholesterol, adipokines, insulin 
and fasted glucose; and are more glucose tolerant. Furthermore, transgenic 
mice perform better on a rotarod challenge and also show a delay in 
reproduction.  
 
Several studies have indicated that resveratrol activates SIRT1 directly [45, 46] 
through a fluorescence assay known as Fluor de Lys, but other studies have 
questioned this finding and shown that measuring SIRT1 activity by fluorescent 
substrate assay could lead to false results [47], since resveratrol only activates 
SIRT1 if the substrate is attached to a fluorophore.  
 It has been reported the effects of SIRT1 deficiency and overexpression on 
mouse learning and memory as well as on synaptic plasticity, and it was 
demonstrated that the absence of SIRT1 impaired cognitive abilities, associated 
with defects in synaptic plasticity. In contrast, brain overexpression of SIRT1 
develops normal synaptic plasticity and memory [48]. Authors conclude the key 
role of SIRT1 in learning, memory and synaptic plasticity in mice. However, 
resveratrol have other beneficial effects apart from SIRT1 activation that 
renders it active in absence of SIRT1. For example, several studies showed that 
resveratrol is a potent activator of AMPK in neuronal cell lines, primary neurons, 
and the brain [49] but these resveratrol-mediated AMPK activation during were 
independent of SIRT1. Furthermore, many of the actions of resveratrol, 
including mitochondrial biogenesis and neurite outgrowth, depended on the 
presence of a functional AMPK complex and its upstream regulator LKB1. 
Moreover, recent studies have found that resveratrol inhibits PDE4 increasing 
cAMP levels  that increases AMPK activity, which leads to an increase in the 
NAD+/NADH ratio and in the activation of SIRT1 [50]. 
 
Resveratrol extends life in numerous species, although some discrepancies 
between laboratories remain unexplained [4]. In mice, resveratrol prevents the 
early mortality associated with obesity [7], and recently it was demonstrated to 
prolong life in lean, healthy animals [8]. The deaths that have been prevented in 
obese mice seem to have resulted primarily from vascular complications, which 
are not a significant cause of mortality in lean mice, but are associated with 
morbidity and mortality in humans. Therefore, the mouse studies provide good 
rationale for studying the effects of resveratrol on human health. However, the 
influence of factors such as interspecies differences in metabolism, genetic 
variation, diet, physical activity, disease and mental health should not be 
underestimated when extrapolating from rodent models. Further experimental 
evidence is needed to clarify the importance of SIRT1 and other potential 
mechanisms in the effects of resveratrol. 
 
Neuronal survival and autophagy: role for resveratrol. 
Autophagy is an intracellular catabolic process involved in protein and organelle 
degradation via the lysosomal pathway [51]. In animals, autophagy works as a 
central process in cellular quality control by removing waste or excess proteins 
and organelles. Impaired autophagy and the age-related decline of this pathway 
favor the pathogenesis of many diseases that occur primarily in old age such as 
neurodegenerative diseases and cancer. The functional efficiency of the 
autophagic–lysosomal system clearly declines during aging, which 
compromises the maintenance of a healthy cell and can lead to certain 
proteinopathies and neurodegeneration typical of aging [52]. Several studies 
have also demonstrated that enhancing autophagic degradation, for example 
with rapamycin, has therapeutic potential in experimental models of protein 
aggregation diseases such as Huntington’s [53] and Parkinson’s diseases [53]. 
The signaling pathways regulating autophagy and the aging process are linked 
to each other at the molecular level. In particular, the repressive effects of the 
mammalian target of rapamycin (mTOR), an evolutionarily conserved protein 
kinase for modulating autophagy, the role of Beclin-1, a repressor or activator of 
autophagy, and the activator LC3B have been described [ 51, 52]. Interestingly, 
recent studies have revealed that different stress resistance and longevity 
signaling pathways such as p53 [54] and SIRT1 [55] are also potent regulators 
of autophagic degradation. Recent studies demonstrate that the advantages of 
consuming polyphenols such as resveratrol, catechin, quercetin, silibinin and 
curcumin may also be connected to autophagy induction. This is associated 
with the negative regulation of SIRT1 on mTOR [556]. Resveratrol reduces the 
activity of mTOR in a SIRT1-dependent manner [57]. Sirtuin 1 interacts with and 
deacetylates pro-autophagic proteins Atg5, Atg7, and Atg8 [55]. Furthermore, 
SIRT1 is shown to deacetylate the major AMPK kinase LKB1, thereby 
increasing its activity and capacity to activate AMPK [57]. Thus, the 
SIRT1/LKB1/AMPK pathway may be involved in regulating autophagy. In 
addition to activating SIRT1, resveratrol has also been shown to inhibit p70 S6 
kinase, thereby suppressing autophagy [58]. It seems that multiple target 
molecules are involved in the regulation of the effects of polyphenols on 
autophagy. Investigations of these molecular pathways would identify the 
molecular target(s) in regulation of autophagy in chronic inflammatory diseases 
such as chronic obstructive pulmonary disease and diabetes, where autophagy 
is deregulated [59-62] and, as mentioned above,  major neurodegenerative 
disorders such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s 
disease [2, 53, 54]. 
 
Resveratrol implication in the inflammation process and 
neurodegeneration. 
The inflammatory trigger could be a variety of stimuli, including tumor necrosis 
factor-α (TNF-α), interleukin-1 (IL-1), T-cell activation signals, reactive oxygen 
intermediates, etc., which promote the activation of NFƙB, the central regulator 
of inflammation [63-65]. A number of studies have demonstrated that resveratrol 
mediates the down-regulation of various inflammatory biomarkers such as TNF-
α, cyclooxygenase-2 (COX2), inducible nitric oxide synthase (iNOS) and 
interleukins [66-69]. This activity seems to depend on some structural features 
of resveratrol such as the number and position of hydroxyl groups and also the 
action of resveratrol on SIRT1. 
Gentilli et al. [70] demonstrated that resveratrol exerts an inhibitory action on 
COX2, acting as an aryl hydrocarbon receptor antagonist and a direct inhibitor. 
Resveratrol also inhibits nitric oxide (NO) generation, cytosolic iNOS protein 
levels and lipopolysaccharide (LPS)-activated macrophages. Moreover, several 
studies have indicated that the phytoalexin inhibits the translocation of p65 to 
the nucleus, thereby blocking the proinflammatory action of NFƙB pathways in 
several tissues. Several studies have reported the suppression of the pro-
inflammatory kinases c-Jun N-terminal kinase-1 (JNK-1) and IκB kinase β. 
(IKKβ), the intra-nuclear binding of NFƙB, a reduction in the expression of TNFα 
and IL-6 in mononuclear cells , and TNFα and C reactive protein plasma 
concentrations after treatment in humans with an enriched resveratrol extract of 
Polygonum cuspidatum [71]. 
As mentioned above, resveratrol has been linked to an increase in PGC1-α, and 
this transcription factor is enriched in tissues with higher oxidative stress. On 
the other hand, the role of PGC1-α in the inflammatory process has been widely 
addressed in the literature, mainly in metabolic diseases, but also in the brain. 
So resveratrol exerts part of its anti-inflammatory activity through the activation 
of the transcriptional role of PGC1-α on well-known mediators of inflammatory 
processes such as several cytokines. 
Therefore, the involvement of multiple intracellular resveratrol targets in 
neuroinflammation seems to be clear, although more studies on the 
structure/activity relationships are required in order to analyze the exact role of 
this effect on the beneficial activity of resveratrol in the treatment and prevention 
of neurodegenerative processes [72]. 
Several toxic paradigms, both in vitro and in vivo, of neuroinflammation have 
been tested with resveratrol. For instance, resveratrol averts neuronal loss in 
several animal models in which neurons are exposed to toxic agents. Rats with 
cognitive loss induced by streptozocin,  that induces a decrease in the central 
metabolism of glucose jointly with a excitotoxic mechanism of neurotoxicity, had 
improved memory and learning (tested by means of maze negotiation and 
avoidance of foot shocks) after being given resveratrol [73]. In another murine 
model, in which rats were injected with colchicine (which disrupts microtubules 
and interferes with axonal and dendritic transport), resveratrol again alleviated 
the cognitive function deficit, measured by the water maze test [74]. Moreover, 
in newborn rats, resveratrol reduced neuronal loss after traumatic brain injury. 
Elderly rats fed pterostilbene, another polyphenol found in grapes and 
blueberries, performed better in the water maze test than those fed a control 
substance, and pterostilbene provided even greater in vitro protection in a 
chemical-induced neurotoxicity model than resveratrol, as well as in a murine 
model of senescence (SAMP8) [75]. 
The neuroprotective role of polyphenols has also been gated with the inhibition 
of microglial function, for example resveratrol exerts anti-inflammatory effects in 
microglia and astrocytes by inhibiting different proinflammatory cytokines and 
key signaling molecules, as NFƙB and the activator protein 1 (AP-1) [76, 77].  
Conclusions 
Much evidence shows that hormetic phytochemicals are an important resource 
for the development of novel neuroprotectants [19,78]. Hormetic 
phytochemicals activate several transcription factors (NFkB, Nrf2 and CREB) 
and modulate the adaptive stress response to various stimuli [19]. The 
autophagy process also has a key role in neuroprotection and has been related 
to the pleiotropic action of resveratrol [79] (Fig. 1).  
Polyphenols may induce epigenetic changes that are neuroprotective. Histone 
acetylation may be implicated in the pathogenesis of several dementing 
illnesses, including Alzheimer’s disease and Parkinson’s disease [80] (Fig. 2). 
As mentioned above, SIRT1, which may be a target of resveratrol action, also 
has histone deacetylase action, which leads to conformational changes in DNA-
wrapped histones that prepare the DNA for transcription by RNA polymerases [ 
81, 82]. Mice engineered with a defect in histone acetylation show greater 
memory deficits in old age [83], so the activity of resveratrol on the histone 
deacetylation role by activation of SIRT1 should not be underestimated. 
In terms of the effectiveness of resveratrol or its derivatives in humans, several 
clinical trials on the use of resveratrol alone or in combination with other 
substances in the treatment of dementia are now under way [see 9 and 13, for 
revision]. 
In light of the evidence presented in this review and in the literature currently 
available, special attention should be given to the possibility of dietary 
countermeasures to fight against age-related neurodegenerative diseases. 
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Figure 1: Protective effects and mechanism of resveratrol in the nervous 
system 
  
Figure 2: Non-exhaustive list of potential benefits of resveratrol on 
neurodegenerative diseases. 
